Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone/Salmeterol 100/50 vs Seretide Diskus
NCT04124094Phase 1Completed
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate nasal spray and salmeterol in asthma (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration and Maximum Plasma Concentration. Started Oct 2019; status: completed.
02
Drugs
fluticasone propionate nasal spraysalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04124094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124094.